{"id":"ap-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4302313","moleculeType":"Small molecule","molecularWeight":"307.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the serotonin receptor, which helps to reduce symptoms of depression and anxiety. This is achieved through the modulation of serotonin levels in the brain.","oneSentence":"AP-101 is a small molecule that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:55.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":"Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I","enrollment":18},{"nctId":"NCT05039099","phase":"PHASE2","title":"A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"AL-S Pharma","startDate":"2021-09-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":73},{"nctId":"NCT05974579","phase":"PHASE1","title":"Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2023-11-23","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT03981536","phase":"PHASE1","title":"A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"AL-S Pharma","startDate":"2019-10-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP-101","genericName":"AP-101","companyName":"AL-S Pharma","companyId":"al-s-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP-101 is a small molecule that targets the serotonin receptor. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}